Travis B. Dick, PharmD, MBA, BCPS, CPEL, FASHP (Travis_Dick@URMC.Rochester.edu) is the Director of Clinical Pharmacy Practice, Research, & Education and PGY1 Pharmacy Residency Program Director at the University of Rochester. He received his PharmD from the University of North Carolina-Chapel Hill and completed both PGY1 Pharmacy and PGY2 Solid Organ Transplant Residencies at Duke University. He also holds an MBA from the University of Utah.
Dick’s leadership in ASHP includes serving as Chair of the Frontline Leaders Advisory Group and Educational Steering Committee for the Section of Pharmacy Practice Leaders, membership on the Council on Education & Workforce Development, guest surveying for pharmacy residency programs, and serving in the House of Delegates. He is the Immediate Past-President of the New York State Council of Health-system Pharmacists and previously served on the Utah Society of Health-system Pharmacists Board of Directors.
The pharmacy profession is at an inflection point as we look to the future. Medication use, misuse, pharmacy deserts, targeted therapies, and drug costs are all on the rise. Increasing threats to the workforce and profession seem ubiquitous: workplace violence, cyber-attacks, drug shortages, eroding margins, industry disruptors, and staffing shortages are just a few. There are also exciting advancements including artificial intelligence, cellular and gene therapies, alternative sites of care, and digital innovations that can revolutionize care delivery.
Now is the time to future-proof the pharmacy profession as I firmly believe pharmacists are best positioned to improve patient care outcomes, innovate healthcare delivery models, and drive positive value for our health-systems. ASHP and the Section are primed to confront uncertainties and capitalize on these opportunities. Harnessing and integrating technology, developing value-based clinical metrics and pharmacy-sensitive indicators, positively influencing population health, and creating care delivery models for a thriving workforce are essential. We can further optimize financial performance by advocating for reform around 340b, pharmacy benefit manager pressures, and creating infrastructure for ultra-high-cost drugs.
If elected, I look forward to offering unique, actionable perspectives on how we can sustainably shape clinical, operational, and financial models. I am honored to be nominated and excited about the opportunity to serve the Section and help ASHP advance pharmacy practice and future-proof our profession.